Prima BioMed Ltd (NASDAQ:IMMP) Stock Has Average Price Target of $110.00

Prima BioMed Ltd (NASDAQ:IMMP) has received a consensus recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $110.00.

Several brokerages have recently commented on IMMP. Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. Jefferies Financial Group upgraded shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday, October 6th.

Prima BioMed Trading Down 5.3%

Shares of IMMP opened at $3.38 on Monday. The business’s fifty day moving average price is $6.34 and its two-hundred day moving average price is $7.72. Prima BioMed has a 52 week low of $3.36 and a 52 week high of $70.60.

Prima BioMed (NASDAQ:IMMP) last released its earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share for the quarter. The firm had revenue of $3.68 million during the quarter.

Prima BioMed Company Profile

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments.